Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/13—Coniferophyta (gymnosperms)
  • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/32—Burseraceae (Frankincense family)
  • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• Redox catalysts are active substances which, due to their biochemical properties, are able to intervene directly or in a physiological manner in the intracellular metabolism regulation.
• these metabolic regulators the most interesting are those that can increase the overall adaptive capacity of the cell.
• Biochemically, however, metabolic changes mean conversions of biomolecules and thus ultimately electron transitions between molecules and molecular systems. This increases the load capacity of the cell (increase in exercise tolerance) without resulting in stress-related microtrauma (e.g., changes in cell organelles).
• An effective remedy in this way is different from compounds such as hormones, nonspecific stimuli, chemotherapeutic agents, etc.
• the effect of the known redox catalyst is presumably achieved by the molecular composite system of the molecular weight bandwidth of 5,000 to 30,000 daltons, in which electron-donor-acceptor reactions are initiated on pathologically altered tissues (electron scavenger effect).
• the effects described above could be demonstrated in in vitro models of leukocyte and fibroblast cultures.
• An antiviral effect of the redox catalyst was found in cultures infected with FV (Friend virus) both without and in combination with ziduvudine (AZT). This is a therapeutic application, for example in HIV-infected patients, with high efficacy and low toxicity possible.
• the object of the present invention is the development of a method which allows the specific adaptation of the already known redox catalysts to certain organs and organ systems or disease symptoms, so that certain metabolic disorders and immune deficiency-sequelae can be treated with hitherto unknown therapeutic effectiveness.
• One aim was therefore to further improve the already known therapeutic effect of the redox catalyst.
• Another object of the present invention is to provide a specifically adapted redox catalyst.
• the vegetable redox catalyst is treated or irradiated with sinusoidal resonance frequencies.
• adaptation is meant the adaptation or loading / loading of organs or organ systems and the redox catalyst with the associated resonance frequencies.
• this includes the adaptation to organs or organ systems, as well as the neutralization of pathogens and parasites.
• the treatment scheme with sinusoidal resonant frequencies includes a frequency generator controlled by a connected computer.
• a frequency generator in principle, any model capable of emitting frequencies in the range of 0.01 Hz to 1 MHz is suitable.
• Well suited, for example, is the model PCG 10 from Vellemann.
• this device is also able to automatically follow certain frequencies in succession.
• any other frequency generator which is technically able to automatically sequence different frequencies one behind the other.
• the frequency generator is further connected to a computer, which serves as a control unit for the frequency generator.
• Irradiation with the frequency generator takes place with radiation, which can be represented by a sinusoidal signal.
• the offset of the sinusoid is preferably in the range of up to about +10, and more preferably up to about +6. Particularly preferred for an offset is a value of about +5, as at higher values, the burden on the patient may become too great. Values below about +5 prolong the treatment phase. However, the offset may also assume negative values of up to about -10, preferably about -5. Negative offset values are particularly useful for treating blockage phenomena such as immune blocks, metabolic blockages (e.g., kidney, liver, and / or spleen), and the like.
• the voltage applied to the frequency generator is up to about 10 volts for adaptation, preferably up to about 6 volts. Particularly preferred is a voltage of about 5 volts, as at higher levels the burden on the patient may become too great.
• both should be individually adjusted to the patient and his or her state of health.
• the individual choice helps to achieve the optimal therapeutic effect for the respective patient.
• the adaptation of the redox catalyst is carried out by irradiation with different frequencies. This process can basically be done in two different ways: First, by having the appropriate frequencies radiated simultaneously (by multi-channel frequency generators) or, second, by applying the respective frequencies one at a time.
• the irradiation time per frequency should be up to about 5 minutes, especially between about 1 and about 4 minutes.
• the irradiation time is about 3 minutes since the capacity of the redox catalyst is limited by its physical properties and amount.
• this irradiation time is individually dependent on the patient and his clinical picture.
• the irradiation time per frequency is preferably about 1 to about 5 minutes, and in most cases should not exceed about 20 minutes per frequency. If the patient is irradiated with a sequence of different sequences, wherein the irradiation time for each individual frequency is in each case about 3 minutes, only a relatively short break of a few seconds is necessary between the irradiations with the respective frequencies.
• the breaks should not be completely abandoned, as they have an important function: In the breaks between the respective irradiations existing infectious agents are mobilized, which can then be neutralized with suitable frequencies. A mobilizing effect is also achieved with regard to the above-described pathological blockages of the metabolic process.
• the patient is connected to the generator by means of parallel connected hand and foot electrodes (HE, FE).
• the positive pole is connected to the right side of the body in a male patient, whereas in female patients the negative pole is used for the right side of the body.
• an additional branch to the container with the redox catalyst can take place, so that frequencies are applied in parallel with frequencies during the course of the therapy (FIG. 1).
• the redox catalyst itself is present either as an ampoule preparation for parenteral administration or in the homeopathic potency level D4 for later oral administration.
• the specifically adapted redox catalyst can be stored for several years without losing its effectiveness.
• organ- or symptom-adapted redox catalyst in a number of pathological metabolic changes or immunobiological Zellbelastungs- weaknesses is possible.
• Another important advantage of this invention over known methods lies in the possibility of permanent use.
• the isolation of the redox catalyst can be carried out in the following manner: starting material are leaves of geranium (Pelargonium odoratissimum), the carnation (Eugenia caryophyllata), myrrh (Commiphora abyssinica, C. molmol, C. schimperi) and / or juniper (Juniperus communis) , The leaves are crushed and slurried in water. The suspension is adjusted to a pH of 9-11 with lye and stirred for at least about 6 hours, preferably for about 48 hours, at 45-50 0 C, more preferably at exactly 48 0 C.
• the redox catalyst must be irradiated with sinusoidal resonance frequencies of a frequency generator; the offset of one frequency is preferably about +5, the voltage is preferably about 10V, the exposure time to the redox catalyst per frequency is preferably about 3 minutes.
• prostate hyperplasia Preferably for prostate hyperplasia, benign
• liver cirrhosis Preferably for liver cirrhosis, posthepatitic
• the specifically adapted redox catalyst can be administered intravenously. Alternatively, it may also be administered orally or as an inhalant solution.
• This dosage form has the advantage that the patient can take the redox catalyst independently at home.
• the patient receives the specifically adapted redox catalyst according to the first or second variant and at the same time additionally irradiated with the corresponding frequencies.
• a pharmaceutical composition contains the specifically adapted plant redox catalyst at a concentration of up to about 300 mg / ml, more preferably from about 50 to about 250 mg / ml, and most preferably at a concentration of about 200 mg / ml.
• the redox catalyst is present as an ampoule preparation in physiological saline (0.9% NaCl solution) for parenteral administration.
• potency levels of D4 to D24 and C4 to C12 in 54% ethanol solution are first prepared from the plant redox catalyst by classical homeopathic potentization method and then fed to the specific adaptation.
• concentration of active compound contained in the mixture varies from about 0.1 to about 2% by weight.
• 100 g of the crushed leaf mixture are slurried in about 1000 ml demineralized water. It is carried out with caustic, NaOH or KOH, adjusted to a pH in Range of 9-11. The mixture is kept at a temperature of about 48 ° C for about 48 hours with constant stirring. Subsequently, the remaining solids are removed by coarse filtration and discarded.
• the resulting solution is adjusted to pH 6.8 by dialysis against a standard phosphate buffer solution. Since a number of non-specific solids (plant proteins or proteins) precipitate during this step, a first purification step is carried out by clear-cell centrifugation at 1000 to 3000 g.
• the further purification of the clear supernatant is carried out first by chromatography on silica gel or aluminum hydroxide, then by two-stage, fractional ultrafiltration with AMICON ® membranes; in the first step, against a 5000 dalton membrane, all biomolecules smaller than 5000 are separated and discarded; As a separation medium, the phosphate buffer solution used above is used.
• the second filtration step is carried out by a membrane with molecular weight separation greater than or equal to 30,000.
• the clear filtrate contains the purified redox catalyst as a molecular composite system with a molecular weight spectrum of 5000-30000.
• the thus purified solution of the redox catalyst is dialyzed against a 0.9% NaCl solution and adjusted to a concentration of about 1 mg / ml.
• the fluorescence excitation spectrum of the active substance is at a wavelength of 450 nm.
• ROK ampoules containing 1 mg / ml concentration of the active substance are used. Injections are given intravenously at 2 ml / 5 days a week as well as with ImI each directly into the breast tissue to the tumor (not into the tumor). Total duration of injections up to 4 weeks (equivalent to 20 injections i.v., 20 injections into the breast tissue). Maintenance dose weekly 2 x 2ml i.m.
• Injections are made intravenously with 4ml / 5 days a week, total duration of
• ROK ampoules containing 1 mg / ml concentration of the active substance are used. Injections are given intravenously with 2ml / the for 5 days a week, total duration of injections, up to 4 Weeks. Thereafter, as a maintenance therapy, the provision of the drug in the form of an inhalant solution with the concentration of 0.5 mg / ml.
• Daily inhalation applications with an Ultrasonic Ivemebler (nebulizer power of particle size: 1-10 microns). Decline in stenocardic symptoms, physical performance subjectively greatly improved.
• the ampoules are administered by retroperitoneal injections to the abdomen.
• ROK ampoules containing 1 mg / ml concentration of the active substance are used. Injections are given intravenously with 1 x 5ml / die, 3 times a week, total duration of injections up to 4 weeks. Subsequent maintenance doses of 1 x weekly with 5ml i.v. Improvement of subjective general condition, decrease of tremor and rigor.
• ROK ampoules containing 1 mg / ml concentration of the active substance are used. Injections are given intravenously with 2ml / the for 5 days a week, total duration of injections up to 4 weeks, then maintenance doses of weekly 2 x 2ml i.m. Fast healing of the fracture line after 4 weeks, general stabilization and density increase of the bone structure (X-ray control) after 6 weeks.
• the plant redox catalyst is prepared in the D4 potency step in 54% ethanol solution and adapted specifically before use. Treatment is by taking 3 drops of the D4 preparation 30 times a day. After the condition of the patient improves and the symptoms of illness diminish, the intake on Ix can be reduced by 30 drops per day. If desired, the application can then be continued permanently.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Alternative & Traditional Medicine (AREA)
• Epidemiology (AREA)
• Botany (AREA)
• Mycology (AREA)
• Diabetes (AREA)
• Biotechnology (AREA)
• Medical Informatics (AREA)
• Biomedical Technology (AREA)
• Microbiology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Hematology (AREA)
• Physical Education & Sports Medicine (AREA)
• Urology & Nephrology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Obesity (AREA)
• Rheumatology (AREA)
• Endocrinology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Gastroenterology & Hepatology (AREA)
• Psychology (AREA)
• Emergency Medicine (AREA)
• Heart & Thoracic Surgery (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38523389

Family Applications (1)

Country Status (2)

Citations (5)

• 2006
  • 2006-05-30 DE DE102006025103A patent/DE102006025103A1/de not_active Withdrawn
• 2007
  • 2007-05-30 WO PCT/EP2007/004780 patent/WO2007137833A1/de active Application Filing

Patent Citations (5)

Also Published As

Similar Documents

Legal Events